Member Info for hectordog

The question has been asked as to why the company had to raise at 50p. My take on this is that that they simply had no option because (probably) they had been warned by the auditors that the latest accounts were unlikely to get a clean report re going concern.

If this is the case then Gardiner simply has to go soonest as he should have foreseen this and warned the BOD well before action was eventually taken.

Events in the next few weeks will show whether this is a correct analysis.

As a separate point how on earth can a company with this size of activities justify £5.4m on ‘Central’ S, G & A costs? Unbelievable!

Are we going to see the 2023 story this Friday? 2022 appeared Friday 28 April 2023.

Might be an interesting read…….with lots of excuses.

And hopefully some retirements/resignations from the BOD.

Agreed, and the chairman who doesn’t seem to have a clue about running a company with excellent prospects and a dominant CEO.

Down another 2.25p today and clearly heading for the 2022 low.

Smith is going to have a very difficult AGM in June when he will undoubtedly face a very hostile group of shareholders.

I think both the chairman and finance director need to go after this shambles. The need for this funding should surely have been foreseen months ago and could have been launched when there was excitement around the progress of AVA6000.

Now checked - it does seem likely that Avacta could get a Nasdaq listing via the ‘Capital Market’ scheme which is specifically designed for smaller companies raising growth capital.

You may be right but I think there is a ‘growth’ section of the market which accepts lower market capitalisations. The alternative is that they might say a Nasdaq listing is now a serious aspiration.

There has been much speculation on this BB about a funding round and I am not going add to that. I simply want to re-state some facts that we already have that MIGHT point in a certain direction IF a funding round is launched.

1. We now have a pretty powerful Nomad team with both Stifel and Peel Hunt on the case.

2. We now have a Chief Business Officer with both big pharma and Nasdaq experience.

3. We now have a Head of R&D with a similar background.

4. We know from the 13 December RNS that a Phase 2 study in the USA is possible in this year.

All this has taken place relatively recently.

The inevitable logic of all this seems to be that IF a funding round takes place, it will be coupled with an announcement about a dual Nasdaq listing. IF this takes place, our shares would no longer qualify for IHT/BPR but I don’t suppose most shareholders will mind given the likely uplift in value that might occur in the short term.

All entirely speculation on my part!

For those who follow such things, NIOX appears to have made a rather good ‘Key reversal’ today which may well presage a significant upward movement.

The NIOX share price has behaved well in the past when patterns have formed/completed.

Watch this space…….

Ah, looks like there was a panic seller on the bell who was either out to do what he achieved or didn’t know how to trade AIM in size.

Extraordinary reaction to trading statement - SP marked down by 7%! Incredible, what do management have to do to satisfy this crap AIM market rigged by brokers for their own purposes?

You don’t need 3 reasons - the simple single answer must be that HC are dropping their shares at every opportunity and have been since they had their last allocation.

W, I understand your point but with the company presently valued at c£340m, a take out price of £500m would succeed as you know the way the market works and there is no block of institutional shareholders that might put up a fight no matter what the BOD might say in defence. If I were CEO of a BP with a particular interest in cancer drugs i think I would take a punt as the amount expended would be petty cash in their scheme of things.

Smith made it very clear that Avacta would keep the IP in AVA6000 but it would 'look to partner the precision platform during 2024' if I heard him correctly. This opens up the prospect of attractive revenue deals next years presumably with significant development pharma companies.

More significantly, in my view, BP casting an eye over AV would not want their options limited by the company already having done deals with their competitors. This therefore brings forward the possibility of a take-out bid, in my view, sooner than later.

Incredibly stupid SP reaction to RNS brought about by s/t traders in the share not having the slightest clue about the fundamentals of this business. I hope they have burnt their fingers and hands.

Looks like the 140p resistance level is going to be taken out today then it really is clear blue sky!

Yes, but the short term idiots who cannot see beyond the end of their noses, sell - look at this morning's trades!

More like a quid.......

As a result of the Grenfell tragedy, building regs now require that ALL steelwork in buildings is coated with intumescent paint. This would seem to provide a great opportunity for Zenova's FP paint.

I think we will see some serious traction in this area before too long. And what about the FX fire extinguisher range which is said to be capable of dealing with the most difficult fires including lithium batteries - another winner.

Explosive! Driven, of course, by wild expectation ahead of next weeks AGM.